Clinical Usefulness of Bone Alkaline Phosphatase in Osteoporosis

Kyd, P; Vooght, K De; Kerkhoff, F T; Thomas, Elizabeth; Fairney, Angela

doi:10.1177/000456329803500603

Cited by 21 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The values for serum calcium, phosphate, total alkaline phosphatase and PTH did not change signi®cantly during the study. Bone marker changes in patients pretreated with etidronate and those not pretreated from this cohort of patients have been reported previously [7,8]. The patients showed a signi®cant decline in bone turnover at 6 months after alendronate treatment, and there was no signi®cant difference in the changes between the etidronatepretreated patients and those not pretreated.…”

Section: Resultssupporting

confidence: 69%

Response to Alendronate in Osteoporosis after Previous Treatment with Etidronate

Fairney

Kyd

Thomas

et al. 2000

Osteoporosis International

View full text Add to dashboard Cite

Bisphosphonates such as etidronate and alendronate are widely accepted as effective agents for the treatment of osteoporosis. However, some physicians find the choice of which one to use in different patients, and the comparative magnitude of response, unclear. Fifty postmenopausal women with osteoporosis [group 1: 27 women who had received 3 years of previous cyclical etidronate treatment, mean age 70.5 years, bone mineral density (BMD) mean T-score lumbar spine (LS) -3.58 and femoral neck (FN) -2.51; group 2: 23 women who had not previously received cyclical etidronate treatment, mean age 73.7 years, BMD mean T-score LS -3.65 and FN -2.96] were treated with 10 mg alendronate daily, to determine whether pretreatment with etidronate affected the response to alendronate, and whether patients who did not respond to etidronate, responded to alendronate. There was a significant increase in LS BMD after 2 years of treatment with alendronate compared with baseline (group 1: 7.84%, p<0.001; group 2: 6.69%, p<0.001), but there was no statistical difference between the groups. In the group 1 patients there was a significant difference between the initial response (at the LS BMD) to 2 years of cyclical etidronate (1.86%) and later response to 2 years of alendronate (7.84%) (p<0.0001). The 10 patients who did not respond at the LS to etidronate alone, showed a significantly better response (mean BMD change +6.3%) when subsequently treated with alendronate (a net difference of 9.3%, p=0.002). In 15 patients who did not respond at the FN to etidronate alone, the mean response to alendronate was +0.96% (a difference of 7%, p= 0.004). This study shows that pretreatment with 3 years of cyclical etidronate is not detrimental to the subsequent LS BMD response to alendronate. There is evidence that alendronate produced a greater bone density response than etidronate, and patients who did not respond to etidronate with an increase in LS bone density, subsequently did so following alendronate.

show abstract

Section: Resultssupporting

confidence: 69%

Response to Alendronate in Osteoporosis after Previous Treatment with Etidronate

Fairney

Kyd

Thomas

et al. 2000

Osteoporosis International

View full text Add to dashboard Cite

show abstract

“…Recent study has also shown that the activity of serum total ALP >129 U/L is used as an indicator for osteoporosis in men [16]. Moreover, the decrease of total ALP has been demonstrated with the treatment with alendronate from 79.7 U/L to 64.8 U/L [17]. The results indicate that total ALP can be used as an indicator to reflect the efficiency of drug treatment for osteoporosis.…”

Section: Bone Formation Biomarkersmentioning

confidence: 98%

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives

2017

View full text Add to dashboard Cite

Bone biomarkers included formation, resorption and regulator are released during the bone remodeling processes. These bone biomarkers have attracted much attention in the clinical assessment of osteoporosis treatment in the past decade. Combination with the measurement of bone mineral density, the clinical applications of bone biomarkers have provided comprehensive information for diagnosis of osteoporosis. However, the analytical approaches of the bone biomarkers are still the challenge for further clinical trials. In this mini-review, we have introduced the functions of bone biomarkers and then recently developed techniques for bone biomarker measurements have been systematically integrated to discuss the possibility for osteoporosis assessment in the early stage.

show abstract

“… 17 B-ALP is more specific for bone and, therefore, more sensitive in detecting the small changes in bone formation seen in osteoporosis. 17 18 OC is considered a specific biomarker of osteoblast function for the evaluation of bone formation rate in osteoporosis. 5 17 The concentration of P1NP and P1CP in serum reflects bone formation rate, 17 as they are produced during conversion of procollagen type 1 to collagen type 1.…”

Section: Bone Turnover Biomarkersmentioning

confidence: 99%

Osteoporosis: Current Concepts

Akkawi

Zmerly

2018

Joints

266

202

View full text Add to dashboard Cite

Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk. Causes of osteoporosis include increasing age, female sex, postmenopausal status, hypogonadism or premature ovarian failure, low body mass index, ethnic background, rheumatoid arthritis, low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications. The diagnosis of osteoporosis is established by measurement of BMD of the hip and spine using dual energy X-ray absorptiometry. According to the World Health Organization criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviation or more below the average value for young healthy women. Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis consists of nonpharmacological interventions, which are recommended for all subjects, and pharmacological therapy in all postmenopausal women who have had an osteoporotic fracture or have BMD values consistent with osteoporosis.

show abstract

Clinical Usefulness of Bone Alkaline Phosphatase in Osteoporosis

Cited by 21 publications

References 20 publications

Response to Alendronate in Osteoporosis after Previous Treatment with Etidronate

Response to Alendronate in Osteoporosis after Previous Treatment with Etidronate

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives

Osteoporosis: Current Concepts

Contact Info

Product

Resources

About